Your browser is no longer supported. Please, upgrade your browser.
Settings
SESN [NASD]
Sesen Bio, Inc.
Index- P/E- EPS (ttm)-0.80 Insider Own0.03% Shs Outstand175.39M Perf Week-1.22%
Market Cap171.49M Forward P/E- EPS next Y-0.26 Insider Trans0.00% Shs Float173.24M Perf Month-17.71%
Income-118.60M PEG- EPS next Q-0.07 Inst Own34.20% Short Float8.77% Perf Quarter-81.75%
Sales17.80M P/S9.63 EPS this Y83.90% Inst Trans58.60% Short Ratio0.76 Perf Half Y-67.98%
Book/sh0.28 P/B2.94 EPS next Y40.30% ROA-71.90% Target Price- Perf Year-36.70%
Cash/sh0.72 P/C1.14 EPS next 5Y- ROE- 52W Range0.70 - 6.04 Perf YTD-39.04%
Dividend- P/FCF- EPS past 5Y35.90% ROI244.80% 52W High-86.91% Beta0.46
Dividend %- Quick Ratio9.30 Sales past 5Y62.60% Gross Margin- 52W Low12.98% ATR0.09
Employees27 Current Ratio9.30 Sales Q/Q- Oper. Margin- RSI (14)30.38 Volatility9.06% 7.75%
OptionableYes Debt/Eq0.00 EPS Q/Q-211.30% Profit Margin- Rel Volume0.65 Prev Close0.82
ShortableYes LT Debt/Eq0.00 EarningsAug 09 BMO Payout- Avg Volume20.01M Price0.79
Recom2.30 SMA20-14.30% SMA50-63.22% SMA200-69.48% Volume7,369,223 Change-3.89%
Aug-16-21Downgrade H.C. Wainwright Buy → Neutral
Jun-11-19Upgrade H.C. Wainwright Neutral → Buy $3
Sep-28-21 01:10PM  
10:15AM  
09:33AM  
09:00AM  
05:30AM  
Sep-27-21 10:54PM  
09:08PM  
08:50PM  
06:09PM  
04:20PM  
04:15PM  
03:20PM  
02:45PM  
01:40PM  
10:30AM  
10:00AM  
09:46AM  
08:34AM  
Sep-26-21 10:11AM  
08:33AM  
Sep-25-21 07:15PM  
Sep-24-21 10:50PM  
08:10PM  
06:36PM  
06:18PM  
03:52PM  
01:20PM  
12:30PM  
12:20PM  
11:50AM  
10:00AM  
09:00AM  
05:23AM  
Sep-23-21 10:35PM  
07:38PM  
07:04PM  
06:17PM  
06:07PM  
04:38PM  
01:22PM  
01:00PM  
11:45AM  
11:00AM  
05:40AM  
Sep-22-21 10:50PM  
09:19PM  
06:15PM  
04:15PM  
04:12PM  
02:16PM  
11:45AM  
11:00AM  
09:36AM  
05:40AM  
Sep-21-21 10:32PM  
07:49PM  
06:14PM  
05:22PM  
05:16PM  
03:41PM  
03:40PM  
02:50PM  
02:25PM  
01:15PM  
09:35AM  
09:00AM  
05:40AM  
Sep-20-21 10:47PM  
07:49PM  
06:24PM  
06:09PM  
03:40PM  
12:50PM  
12:15PM  
05:50AM  
Sep-19-21 10:38PM  
10:21AM  
08:33AM  
Sep-18-21 04:30PM  
11:24AM  
Sep-17-21 10:00PM  
08:05PM  
06:36PM  
05:58PM  
04:30PM  
04:07PM  
02:30PM  
02:15PM  
01:21PM  
01:00PM  
11:30AM  
11:00AM  
09:45AM  
09:00AM  
06:00AM  
Sep-16-21 11:00PM  
06:17PM  
04:16PM  
11:35AM  
11:30AM  
Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. The company's lead product candidates include Vicinium, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC); and VB6-845d, a product candidate for use in the treatment of various types of an anti-epithelial cell adhesion molecule (EpCAM)-positive solid tumors. It also develops Vicinium in combination with Durvalumab, which is in Phase I clinical trials for use in the treatment of BCG-unresponsive NMIBC; and Vicinium in combination with AstraZeneca's checkpoint inhibitor for the treatment of squamous cell carcinoma of the head and neck. Sesen Bio, Inc. has an agreement with Leiden University Medical Center to co-develop an imaging agent. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.